Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
- 31 July 2008
- journal article
- case report
- Published by Elsevier in Leukemia Research
- Vol. 32 (7), 1153-1156
- https://doi.org/10.1016/j.leukres.2007.11.010
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Managing plasma cell leukemiaLeukemia & Lymphoma, 2007
- Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletionLeukemia, 2006
- Proteasome inhibitors: antitumor effects and beyondLeukemia, 2006
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Bortezomib is effective in primary plasma cell leukemiaLeukemia & Lymphoma, 2006
- CD27‐triggering on primary plasma cell leukaemia cells has anti‐apoptotic effects involving mitogen activated protein kinasesBritish Journal of Haematology, 2004
- Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique HématologiqueBlood, 2001
- The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myelomaLeukemia, 1998